Post-Thrombolysis Rebleed During Catheter-Directed Therapy
A 58-year-old man is on day 2 of catheter-directed thrombolysis for an extensive left iliofemoral DVT. Current infusion: alteplase 0.5 mg/hr via a multi-sidehole catheter in the common femoral vein. Baseline fibrinogen 310 mg/dL; this morning's fibrinogen is 165 mg/dL. Over the last hour the nurse reports oozing at the sheath site that soaked two gauze pads, and the patient now describes new left groin pain and swelling. Vitals: BP 148/88, HR 96, SpO2 97%. Hemoglobin dropped from 12.4 to 10.9 g/dL. The interventionalist is in another case and asks you, the technologist, to gather data and prepare the room while they finish.
1. What data and immediate actions should you prioritize before the interventionalist arrives, and what is your reasoning?
Read the worked answer
Priorities are (1) characterize the bleeding and hemodynamics, (2) verify the infusion status, and (3) prepare for possible intervention.
- Trend the numbers, don't just read them. Fibrinogen fell from 310 to 165 mg/dL and Hgb dropped 1.5 g/dL in a short interval. A falling fibrinogen plus a falling Hgb plus a new groin hematoma suggests a clinically significant bleed, not just superficial oozing. Report the trend, not a single value.
- Hold or pause the lytic per protocol only if your institution's standing order or the responsible physician authorizes it - the technologist does not independently stop a physician-ordered infusion, but you should immediately notify the physician and document the request. Many protocols pause alteplase for significant bleeding or fibrinogen below a threshold (commonly ~100–150 mg/dL); the exact threshold is institutional.
- Assess and mark the site. Note size and firmness of the groin swelling, mark the borders, apply direct manual pressure per policy, and check distal pulses and neuro status.
- Prepare the room for possible ultrasound to evaluate for hematoma/pseudoaneurysm and for possible sheath removal, reversal, or covered-stent placement. Have blood products and reversal agents (e.g., protamine if heparin is also infusing) coordinated with the physician/pharmacy.
- Communicate clearly using SBAR: situation, background (day 2 CDT, current rate), assessment (trending fibrinogen, Hgb, new hematoma), recommendation (physician at bedside).
2. The interventionalist asks whether to continue, reduce, or stop the infusion. How should the team frame the decision, and what monitoring changes follow?
Read the worked answer
Frame it as a risk-benefit judgment the physician owns, informed by objective data:
- Arguments to stop/reduce: active bleeding with hemodynamic trend, falling fibrinogen, expanding hematoma. A retroperitoneal bleed is the feared complication with high femoral access and can present with groin/back pain and dropping Hgb without visible external bleeding - the new pain and swelling warrant urgent evaluation (ultrasound and possibly CT).
- Arguments to continue cautiously: clot burden is large and lytic effect may be partial; stopping risks re-thrombosis.
A common middle path is to pause the lytic, obtain imaging to exclude retroperitoneal hematoma or pseudoaneurysm, recheck fibrinogen and Hgb, and resume at a lower dose only if bleeding is controlled and labs permit - but the decision and thresholds are physician- and protocol-driven.
Monitoring changes if continued: more frequent (e.g., q2–4h) fibrinogen and Hgb, frequent neurovascular checks, sheath-site inspection each shift and with each vital sign check, strict bed rest/immobilization of the access limb, and a low threshold to re-image. Document every communication and every change with time stamps.